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b cell dysfunction with subsequent apoptosis is considered a significant contributor to the devel-
opment of type 2 diabetes. Emerging data from Talchai et al. suggest b cell dedifferentiation as
an alternative mechanism of insulin insufficiency that might be more amenable to intervention in
at least a subset of patients.Type 2 diabetes (T2D) is characterized by
a steady decline in insulin secretion from
pancreatic b cells, resulting in poorly
regulated blood glucose levels that cause
long-term complications in patients. It is
widely accepted that b cells undergo
premature programmed cell death as a
consequence of exhaustion caused by
unsustainable demands and that this
naturally results in a reduction in circu-
lating insulin (Chang-Chen et al., 2008).
Talchai and colleagues now present an
alternative scenario to explain compro-
mised b cell function by demonstrating
that adult murine b cells are modified in
their differentiation state under conditions
of physiological stress and assume a
more progenitor-like state that permits
conversion to other pancreatic endocrine
cell types (Talchai et al., 2012).
Pancreatic b cells are highly sophisti-
cated cells that respond to increases in
blood glucose concentration with a rapid
and commensurate release of insulin.
Numerous physiological demands, in-
cluding aging, pregnancy, and obesity,
introduce stresses on the ability of the
b cell to maintain normoglycemia. Talchai
et al. now demonstrate that, under certain
conditions of cellular stress, the b cell
relies on a specific transcription factor
for maintenance of cellular identity.
FoxO1, a member of the FoxO family
of transcription factors, has previously
been implicated in integrating cellular
responses to physiological stress and
regulation of b cell mass (Buteau and Ac-
cili, 2007). The current study reports that
ablation of FoxO1 in murine b cells has
little effect when the demand on b cells
is low. In contrast, loss of the factor inb cells exposed to sustained stress
results in a profound reduction of insulin-
producing cells. Surprisingly, this re-
duction is not due to accelerated b cell
death but, rather, is caused by the
dramatic deconstruction of the mature
b cell state. Transcription factors that
activate insulin gene expression are
missing, together with processing en-
zymes required for the production of the
mature hormone and granules normally
storing the insulin peptides in high
concentrations. In short, FoxO1-deficient
b cells are stripped of all functional
attributes by unraveling the differentia-
tion process that the cells have gone
through during development. Remark-
ably, the mutant b cells may have re-
gressed back along their original differen-
tiation path, as they now express markers
that are normally observed in multipotent
endocrine progenitors. In other words,
b cells have stepped back in ontogenic
time to assume a stage similar to the
one they progressed through during
organ development (Figure 1).
Though it is unlikely that the differentia-
tion state assumed by the FoxO1 null
cells is identical to the embryonic pro-
genitor state found within the developing
pancreas, dedifferentiated b cells can ex-
press other endocrine hormones. Also,
plasticity of fate within the endocrine
lineage has been recorded in mouse
models of b cell depletion or ectopic
expression of key regulatory factors (Col-
lombat et al., 2007; Thorel et al., 2010).
Importantly, decreased FoxO1 expres-
sion, reduction in the number of insulin-
producing cells, and the presence of
glucagon-expressing cells that are alsoCell 150, Seppositive for b cell markers were detected
in other mouse models of T2D that
are not driven by the genetic loss of
FoxO1.
The findings described by Talchai and
coworkers are important, as they beg
the question of whether a compromised,
dedifferentiated b cell (instead of b cell
death) might be the culprit in a subset
of T2D cases. Does cellular dedifferentia-
tion provide b cells with an advantage to
cope with the high demand posed by
certain physiological conditions? For
instance, during endoplasmic reticulum
(ER) stress, mechanisms that are de-
signed to ensure restoration of cellular
functions can also initiate cell destruc-
tion if the underlying causes are not
resolved (Oslowski and Urano, 2011).
b cells are foremost hormone-producing
cells, and this capacity to generate
enough insulin can be exhausted under
certain physiological conditions. Dediffer-
entiation, defined by reduction of all
components of the insulin sensing, pro-
duction, and secretion machinery as
seen upon FoxO1 elimination, would
dramatically reduce the need to perform
at full capacity and might provide a
shorter path to regeneration once the
demand is reduced, as happens after
pregnancy. In contrast, unabated
demand caused by obesity and insulin
resistance would prevent regeneration
and result in further regression away
from a mature b cell state.
If this scenario is correct, then the
disabled b cells could present a window
of opportunity during T2D progression
when it might be possible to reverse this
state and regain fully functional cells. Intember 14, 2012 ª2012 Elsevier Inc. 1103
Figure 1. FoxO1 Plays a Role in Maintaining b Cell Identity
Under normoglycemic conditions, FoxO1 primarily localizes to the cytoplasm
in mature, insulin-producing b cells. Under conditions of mild hyperglycemia,
FoxO1 is seen to partially localize to the nucleus, with an observable reduction
in insulin staining. In mouse models that exhibit severe hyperglycemia, FoxO1
is greatly diminished in the b cell, along with reduced insulin. Similarly, genetic
ablation of FoxO1, combined with physiological stressors such as aging,
leads to islets lacking FoxO1 and insulin expression that continue to be
populated by endocrine cells as ascertained by chromogranin positivity.
These dedifferentiated b cells re-express, at least transiently, Ngn3, Oct4, and
L-myc, suggesting a more progenitor-like state. Lineage tracing demon-
strates that a fraction of the remaining endocrine cells are derived from b cells
that have repressed the b cell program. Whether such a mechanism of
dedifferentiation occurs in human disease remains to be seen. Finally,
a reversal of fate, from the dedifferentiated b cell into a fully functional b cell
instead of other endocrine cell types, would potentially have great therapeutic
value.fact, transient loss of the b cell
differentiation state has previ-
ously been noted upon inap-
propriate activation of the
Hedgehog signaling pathway
normally excluded from adult
b cells (Landsman et al.,
2011). Thus, conditions likely
exist during which b cells
possess the capacity to re-
generate. Whether such tran-
sient states occur during
T2D progression and whether
b cell regeneration is possible
remains to be explored.
A critical question not ad-
dressed is the relevance of
the reported findings to the
human condition. A prediction
stemming from the current
analysis would be that, in a
subset of human T2D patients
with mild hyperglycemia,
nuclear FOXO1 expression
would be present in insulin-
positive cells. Islets of
patients with longstanding
disease should be devoid of
both insulin and FOXO1.
Furthermore, it would need to
be tested whether ‘‘a-like’’
cells that express some b cell
markers can be found in
human T2D islets. Talchai
and colleagues have ob-
served hyperglucagonemia in
FoxO1mutant mice; however,
it is not clear whether this
is caused by the fact that
the glucagon-positive cells
derived from b cells are func-
tionally compromised hybrids
due to the inappropriate ex-
pression of b cell transcriptionfactors. Additional questions concern the
significance of the appearance of the
pluripotency marker Oct4. Is the tran-
scription factor expressed purely as
a consequence of FoxO1 activity, or1104 Cell 150, September 14, 2012 ª2012 Eldoes it play a functional role in hindering
the differentiation of the b cell? Similarly,
the scant appearance of mesenchymal
markers (that costain with glucagon-
positive cells) raises more questions.sevier Inc.Do the dedifferentiating b
cells undergo an epithelial-
to-mesenchymal transition
prior to adopting an a cell
fate? Is there a requirement
for this step to occur?
With 79 million adult
Americans considered as pre-
diabetic, it is imperative that
we obtain a complete picture
of how the disease develops
and how we can interfere
with its progression. The es-
tablishment of transient and
potentially reversible dediffer-
entiationofbcells asacontrib-
utor to T2D might open up
new avenues for therapeutic
intervention.
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